Extensively drug-resistant Haemophilus influenzae - emergence, epidemiology, risk factors, and regimen. 2020

Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
Department of Laboratory Medicine, E-DA Hospital, Kaohsiung, Taiwan.

Concern about Haemophilus influenzae infection has been increasing over recent decades. Given the emergence of H. influenzae with severe drug resistance, we assessed the prevalence of as well as risk factors and potential therapies for extensively drug-resistant (XDR) H. influenzae infection in Taiwan. In total, 2091 H. influenzae isolates with disk diffusion-based antibiotic susceptibility testing from 2007 to 2018 were enrolled. H. influenzae strains resistant to ampicillin, chloramphenicol, levofloxacin, and trimethoprim-sulfamethoxazole tended to be isolated from patient wards (≧41%), whereas those resistant to amoxicillin-clavulanate, cefotaxime, and cefuroxime were more likely to be isolated from intensive care units (approximately 50%). XDR H. influenzae was first identified in 2007, and its incidence did not significantly change thereafter. Overall prevalence of single, multiple, and extensively drug-resistant H. influenzae over 2007-2018 was 21.5% (n = 450), 26.6% (n = 557), and 2.5% (n = 52), respectively. A stepwise logistic regression analysis revealed that blood culture (odds ratio: 4.069, 95% confidence intervals: 1.339-12.365, P = 0.013) was an independent risk factor for XDR H. influenzae infection. No nosocomial transmission of XDR H. influenzae observed. Antibiotic susceptibility testing results demonstrated that cefotaxime was effective against 78.8% (n = 41) of the XDR strains. The presence of XDR H. influenzae strains was identified in Taiwan, and cefotaxime was efficacious against most of these strains.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002701 Chloramphenicol An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D005260 Female Females
D006192 Haemophilus Infections Infections with bacteria of the genus HAEMOPHILUS. Hemophilus Infections,Haemophilus influenzae Infection,Haemophilus influenzae Type b Infection,Hib Infection,Infections, Haemophilus,Infections, Hemophilus,Haemophilus Infection,Haemophilus influenzae Infections,Hemophilus Infection,Hib Infections,Infection, Haemophilus,Infection, Haemophilus influenzae,Infection, Hemophilus,Infection, Hib
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae

Related Publications

Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
June 2013, Antimicrobial agents and chemotherapy,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
March 1982, Antimicrobial agents and chemotherapy,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
January 2018, PloS one,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
September 1981, The Journal of pediatrics,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
March 2007, Emerging infectious diseases,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
December 2012, Future microbiology,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
January 2014, Clinical epidemiology,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
January 2014, The clinical respiratory journal,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
September 2010, Infectious disease clinics of North America,
Pei-Yi Su, and Ay-Huey Huang, and Chung-Hsu Lai, and Hsiu-Fang Lin, and Tsun-Mei Lin, and Cheng-Hsun Ho
January 2008, Revista portuguesa de pneumologia,
Copied contents to your clipboard!